A Reality Check on BP Goals and Optimizing Patient Adherence to Treatment

Introduction

BP Classification: JNC7 vs 2017 ACC/AHA HTN Guidelines

BP Thresholds and Therapy Goals in Patients With HTN According to Clinical Conditions

Prevalence of HTN in the US According to JNC7 and 2017 ACC/AHA Guidelines

Potential Challenges With Labeling a Healthy Person as Hypertensive

2017 ACC/AHA Guidelines and the Older Adult

BP Management and CV Risk in Older Adults

Results From SPRINT

Considerations Regarding Results of the SPRINT Study

2017 ACC/AHA Recommendations for BP Treatment in the Context of CVD Risk

2017 ACC/AHA Recommendations for BP Treatment in the Context of CVD Risk (cont)

2017 ACC/AHA Recommendations for Use of Nonpharmacological Therapy

Concerns Regarding 2017 ACC/AHA Recommendations for Nonpharmacological Therapy

An Alternate Approach to Starting Nonpharmacological Therapy

Concerns Regarding 2017 ACC/AHA Recommendations for Nonpharmacological Therapy (cont)

European Response to New US Guidelines

BP Reduction and the Role of FDC Therapy

Adherence to Antihypertensive Treatment and BP Changes in Initially Nonadherent Patients in the UK

Combination Therapy Increases BP-Lowering Much More Effectively Than Monotherapy

Selection of Antihypertensive Drug Combinations

FDC Therapy: A Practical Necessity

Summary

Summary (cont)

Abbreviations

Abbreviations (cont)